Drugs that contain Ceftolozane Sulfate; Tazobactam Sodium
1. List of Zerbaxa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7129232 | CUBIST PHARMS LLC | Cephem compounds |
May, 2028
(4 years from now) | |
| US8476425 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(9 years from now) | |
| US8685957 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(9 years from now) | |
| US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028963 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(9 years from now) | |
| US9724353 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(9 years from now) | |
| US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
| US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(10 years from now) | |
| US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
| US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(10 years from now) | |
| US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
| US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(11 years from now) | |
| US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(11 years from now) | |
| US10125149 | CUBIST PHARMS LLC | Synthesis of cephalosporin compounds |
Aug, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 19, 2019 |
| New Patient Population (NPP) | Apr 21, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Dec 19, 2024 |
NCE-1 date: 2023-12-20
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associate...
Dosage: POWDER;INTRAVENOUS
ZERBAXA family patents
58
United States
9
European Union
8
Australia
6
China
6
Japan
3
Canada
3
Korea, Republic of
2
Spain
2
Hong Kong
2
Brazil
2
EA
2
New Zealand
2
Mexico
1
Austria
1
Denmark
1
Germany
1
Ukraine
1
Morocco
1
Argentina
1
Peru
1
Israel
1
Chile
1
Portugal
1
Taiwan
1
Netherlands
1
South Africa
1
Luxembourg
1
Tunisia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic